HKeyBio is building HKEY-AI4AI-Atlas™ 1.0, its AI-Assisted Autoimmune Model Data Atlas. The internal capability-building initiative uses AI-assisted dataset curation, standardization and retrieval to ...

HKeyBio is building HKEY-AI4AI-Atlastm 1.0, its AI-Assisted Autoimmune Model Data Atlas. The internal capability-building initiative uses AI-assisted dataset curation, standardization and retrieval to ...

Below is Alston & Bird’s Health Care Week in Review, which provides a synopsis of the latest news in health care regulations, notices, and ...

HKEY-AI-NAM-Bridge™ 1.0 connects AI predictions, new approach methodologies and in vivo evidence for more targeted ...

Pharmacodynamic effects in the human brain and energy metabolism biomarker data presented at AAIC support further clinical development of VNA-318 ...

NeuroTherapia, Inc., a clinical-stage company focused on developing oral therapies for neurodegenerative diseases, will be presenting data from its recently completed Phase 2a clinical trial in ...

Researchers identify the antibiotic concentration where bacteria may be most likely to develop dangerous drug resistance.

UB researcher Nicholas Smith joins Stanford’s NIH-funded Center for Phage Pharmaceuticals to study phage therapy for ...

The genetic disease cystic fibrosis (CF) causes the lungs to fill with mucus, which provides the perfect breeding ground for ...

TTI-109 delivered TTI-101-equivalent exposure with improved tolerability and meaningful reductions in disease-relevant STAT3-driven immune cell ...

Optimization of antiviral drug combinations remains challenging because exhaustive measurement of dose–response spaces is experimentally impractical. Although Bliss-based pharmacodynamic models are ...

The program supports early tolerability assessment, PK/TK-linked safety evaluation, immune-related risk screening, and pre-GLP dose design for biologics and immunomodulatory drug programs ...